Novanta Inc. reports developments as a Nasdaq-listed supplier of core technology solutions for medical, life science and advanced industrial original equipment manufacturers. Its updates center on precision medicine, precision manufacturing, robotics and automation, and advanced surgery, including laser beam steering and scanning, laser sources, robotic and precision motion technologies, medical insufflators, endoscopic pumps and integrated operating room technologies.
Company news commonly covers quarterly earnings releases, conference calls, investor presentations, OEM design wins, product and technology collaborations, and capital actions tied to balance-sheet and securities structure. Recent themes include motion control and sensing technologies for robotics certification environments and tangible equity unit financing.
Novanta (Nasdaq: NOVT) will release its third-quarter 2026 results after U.S. financial markets close on November 9, 2026. A conference call to discuss the results will follow on November 10, 2026, at 8:00 a.m. ET, with a live webcast available through the investor section of its website. An audio replay will be available approximately three hours after the call concludes and remain accessible until December 28, 2026.
Novanta (Nasdaq: NOVT) announced that Chief Financial Officer Robert Buckley and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY.
Novanta describes itself as a global supplier of core technology solutions for medical and advanced industrial original equipment manufacturers, focusing on precision medicine, medical solutions, and robotics and automation.
Novanta (Nasdaq: NOVT) reported second quarter 2026 GAAP revenue of $265.8 million, up 10.3% year over year, with organic growth of 9.3%. GAAP net income rose to $12.5 million and diluted EPS to $0.30, while Adjusted EBITDA increased 16.4% to $60.7 million and Adjusted Diluted EPS grew 17.1% to $0.89.
Automation Enabling Technologies revenue reached $136.2 million and Medical Solutions $129.6 million. Operating cash flow was $64.9 million versus $15.1 million a year ago. According to Novanta, it closed the Riverpoint Medical acquisition, expects it to be immediately accretive, and now guides Q3 2026 revenue to $300–$304 million and full-year 2026 revenue to $1,130–$1,140 million, with higher Adjusted EBITDA and Adjusted EPS targets that incorporate Riverpoint.
Novanta (Nasdaq: NOVT) has completed its acquisition of Riverpoint Medical from Arlington Capital Partners, adding a category leader in minimally invasive surgical consumables, including advanced surgical fibers for sports medicine, trauma and cardiovascular procedures. According to Novanta, Riverpoint’s business is growing revenue and cash flow at about twice Novanta’s rate.
The company expects the deal to roughly double recurring medical consumables revenue to about $300 million and increase medical end-market exposure to 60% of total revenue. Management also cites a potential $2 billion incremental addressable market via shared OEM customer relationships and a strengthened FDA-registered manufacturing footprint.
Novanta projects the transaction will generate a high single-digit return on invested capital by year three, meet its return hurdle by year five, and be immediately accretive to organic growth, adjusted gross margin, adjusted EBITDA growth and margins, and cash flows. The acquisition is expected to add $0.18–$0.25 of adjusted EPS in 2027, with further details on 2026 impacts to come on the next earnings call. Riverpoint Medical will be reported within Novanta’s Medical Solutions segment.
Novanta (Nasdaq: NOVT) will release its second quarter 2026 financial results after the close of U.S. markets on Wednesday, August 5, 2026. The company will host a conference call on Thursday, August 6, 2026 at 8:00 a.m. ET to discuss the results.
Investors can join by dialing (888) 346-3959 or via live webcast on the Events & Presentations page in the Investors section of www.novanta.com. An audio webcast replay will be available about three hours after the call and remain accessible until Monday, October 5, 2026.
Novanta (Nasdaq:NOVT) announced that Chief Financial Officer Robert Buckley and Chief Operating Officer Chuck Ravetto will present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026, in White Plains, New York.
Novanta (NASDAQ:NOVT) entered a securities purchase agreement for a $300 million private placement of common shares to institutional and other accredited investors. Investors will buy 2,142,857 shares at $140.00 per share. Closing is expected on or about June 11, 2026, subject to customary conditions.
The shares are unregistered under the Securities Act and may only be resold under an effective registration statement or exemption. A registration rights agreement requires Novanta to register the resale of these shares.
Novanta (NASDAQ:NOVT) agreed to acquire Riverpoint Medical, a minimally invasive surgical consumables leader, for $1.2 billion upfront plus a $250 million milestone in Q1 2027. Closing is expected in Q3 2026.
The deal is projected to double recurring medical consumables revenue to about $300 million, deepen medical revenue mix to 60%, add a $2 billion addressable market, and be accretive to adjusted EPS and margins while keeping net leverage near 2.7x.
Novanta (Nasdaq:NOVT) announced that Chief Financial Officer Robert Buckley will present at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, in New York, NY.
The appearance highlights Novanta’s participation in a major healthcare investor conference.
Novanta (Nasdaq:NOVT)/b) announced that Chief Financial Officer is scheduled to present at the Baird 2026 Global Consumer, Technology & Services Conference on Wednesday, June 3, 2026, in New York, NY.
The event offers investors an opportunity to hear from Novanta's leadership.